PRICE SCHEDULE M-21
`
`‘
`
`The price schedule below applies to all the products that are given the M-21 price code.
`
`Catalog items with their assigned price codes appear in the Alphabetical Listing of
`
`Products beginning on Page 21.
`
`Products are sold in lots of 25, 50, and 100 pellets.
`
`Doses ofpellets reflect the total amount ofnet active product released over 21 days.
`
`I
`
`TWENTY—ONE DAY RELEASE
`
`PRICEINUMBER OF PELLETS
`
`SI) pellets
`
`'25 pellets
`
`Total Dose
`
`nigfpellel
`
`‘
`
`l('_|{} pellets
`
`A combination of multiple dosages in one lot, for any specified
`product, is also available. PLEASE INQUIRE.
`
`FOR .¢\l)I)El) CON‘ \-WZNIENCE PLACE YOUR ORDI-LR ON LINE AT
`W W W.! N N UV RS R C H. C O M
`
`We Deliver What You Expect With Confidence
`
`Astrazeneca Ex. 2044 p. 74
`
`

`
`PRICE SCHEDULE M-60
`
`The price schedule below applies to all the products that are given the M—60 price code.
`
`i‘
`
`Catalog items with their assigned price codes appear in the Alphabetical Listing of
`
`Products beginning on Page 21.
`
`Products are sold in lots of 25, 50, and 100 pellets.
`
`Doses of pellets reflect the total amount of net active product released over 60 days.
`
`
`
`Total Dose
`
`niglpellet
`
`SIXTY DAY RELEASE
`|
`PRICE!NUMBER OF PELLETS
`
`25 pellets
`
`S0 pellets
`
`lill} pellets
`
`A combination of multiple dosages in one lot, for any specified
`product, is also available. PLEASE INQUIRE.
`
` /OSE
`
`>)>>>>))))))))>>>)§\
`Q))))))))))))))
`‘RELEASE
`
`)))))))))))
`
`
`
`
`
`
`
` \ \n~
`
`FOR Al}I}FID (I()NV|*lNlENC‘E f'I..=\(.‘E \"'(}UR (1 RDER ON LINE AT
`W W W. I NNO\"RSRCH.C()M
`
`Reduce Experimental Variables
`
`Astrazeneca Ex. 2044 p. 75
`
`

`
`
`
`Total Dose
`
`nlgfpellet
`
`i
`
`25 pellets
`
`PRICE!NUMBER OF PELLETS
`
`51} pellets
`
`101} pellets
`
`PRICE SCHEDULE M—90
`
`
`The price schedule below applies to all the products that are given the M-90 price code.
`
`Catalog items with their assigned price codes appear in the Alphabetical Listing of
`
`Products beginning on Page 21.
`
`Products are sold in lots of 25, 50, and 100 pellets.
`
`Doses ofpellets reflect the total amount ofnet active product released over 90 days.
`
`NINETY DAY RELEASE
`
`A combination of multiple dosages in one lot, for any specified
`product, is also available. PLEASE INQUIRE.
`
`FOR ADDICD CONV'ENlE:\'CE PLACE YOUR ORDER ON LINE AT
`W WW.I.'\lNO\-“RS RCTH.C0.’\rl
`
`Increase Data Reproducibility
`
`Astrazeneca Ex. 2044 p. 76
`
`

`
`PRICE SCHEDULE N-21
`
`The price schedule below applies to all the products that are given the N-21 price code.
`
`Catalog items with their assigned price codes appear in the Alphabetical Listing of
`
`Products beginning on Page 21.
`
`Products are sold in lots of 25, 50, and 100 pellets.
`
`Doses of pellets reflect the total amount of net active product released over 21 days.
`
`i
`
`TWENTY—ONE DAY RELEASE
`
`
`
`PRICEl'NU1\*'IBER OF PELLETS
`
`50 pellets
`
`25 peliels
`
`Total Dose
`
`lng/pellet
`
`1
`
`100 pellets
`
`A combination of multiple dosages in one lot, for any specified
`product, is also available. PLEASE WQUIRE.
`
`THE SHORTEST DISTANCE BETWEEN
`
`YOU AND GOOD RESEARCH
`
`RESULTS IS IRA.
`More Time For Creative Research
`
`FOR ADDED CON\*'I+INIENC'Fl PLACE YOUR ORDER ON LINE AT
`W W WJ N N (}\''''R S RC H .(.‘0 M
`
`Astrazeneca Ex. 2044 p. 77
`
`

`
`
`
`PRICE SCHEDULE N-60
`
`The price schedule below applies to all the products that are given the N-60 price code.
`
`Catalog items with their assigned price codes appear in the Alphabetical Listing of
`
`Products beginning on Page 21.
`
`Products are sold in lots of 25, 50, and 100 pellets.
`
`Doses ofpellets reflect the total amount ofnet active product released over 60 days.
`
`I
`
`SIXTY DAY RELEASE
`
`PRICEXNUMBER OF PELLETS
`
`S0 pl.-llcls
`
`25 pellets
`
`Total Dose
`
`mgfpellet
`
`‘
`
`I00 pellets
`
`
`
`A combination of multiple dosages in one lot, for any specified
`product, is also available. PLEASE INQUIRE.
`
`
`
`We Put Management In Time
`
`Astrazeneca Ex. 2044 p. 78
`
`

`
`
`
`PRICE SCHEDULE N-90
`
`The price schedule below applies to all the products that are given the N-90 price code.
`
`Catalog items with their assigned price codes appear in the Alphabetical Listing of
`
`Products beginning on Page 21.
`
`Products are sold in lots of 25, 50, and 100 pellets.
`
`Doses of pellets reflect the total amount of net active product released over 90 days.
`
`NINETY DAY RELEASE
`
`
`
`Total Dose
`
`I
`
`PRlC.E;’NLlMBER OF PELLETS
`
`50 pellets
`
`I00 pellets
`
`A combination of multiple dosages in one lot, for any specified
`product, is also available. PLEASE INQUIRE.
`
` Time flu-[mar Pnlldg
`
`We Help Manage Time
`
`Astrazeneca Ex. 2044 p. 79
`
`

`
`PRECISION TROCHAR
`
`
`
`Please View pages 81 and 123 for trochar and pellet
`
`implantation information.
`
`(Trochar can also be used for tissue transplantation.)
`
`. H
`
`E1
`
`
`
`‘\ l I Hi.
`.
`.un\u-;r
`
`I
`'
`
`
`
`Pellets Capture The Change In Research
`
`72
`
`Astrazeneca Ex. 2044 p. 80
`
`

`
`

`
`
`
`
`
`Astrazeneca Ex. 2044 p. 82
`
`

`
`17B-ESTRADIOL AND TAMOXIFEN PELLETS FOR TUMOR
`
`GROWTH & REGRESSION IN IMMUNO-DEFICIENT MICE.
`
`
`It has been established that the growth and regression of estrogen-dependent
`
`tumor tissue in mice is dependent upon three factors:
`
`1. The tumor tissue itself.
`
`2. A healthy and untraumatized mouse.
`
`3. Exogenous estrogen or anti-estrogen ready-to-implant pellets
`from Innovative Research of America.
`
`The most commonly used 60-day and 90-day pellets in mice are listed below in these charts:
`
`Catalog
`
`Product
`
`Total Dose
`
`Pellet
`
`25
`
`50
`
`60-Day Release Pellets
`
`mglp
`
`Size
`
`Pellets
`
`Pellets
`
`Number
`
`Description
`17 ls-Estradiol
`
`17 ls-Estradiol
`
`17 B-Estradiol
`
`‘I7 lS—Estradio|
`
`Tamoxifen
`
`(free base)
`
`Placebo
`
`These pellets are designed for simple subcutaneous implantation in mice with a 10 Gauge Precision Trochar (Catalog
`
`No. MP~l82 - $240.00 each). NOTE: Other products and dosages that can also be used in mouse studies are found
`throughout this catalog.
`
`90-Day Release Pellets
`
`
`
`Placebo
`
`100
`
`Pellets
`
`Catalog
`
`Number
`
`Product
`
`-rota, Dose
`
`Pellet
`
`25
`
`50
`
`mg/in
`
`Size
`
`Pellets
`
`Pellets
`
`Description
`17 r$.—Estradio|
`
`17 ls-Estradiol
`
`1? rs-Estradiol
`
`17 I3-Estradiol
`Tamoxifen
`
`(free base)
`
`These pellets are designed for simple subcutaneous implantation in mice with a 10 Gauge Precision Trochar (Catalog
`No. MP—182—$240.00 each). NOTE: Other products and dosages that can also be used in mouse studies are found
`throughout this catalog.
`73
`
`Astrazeneca Ex. 2044 p. 83
`
`

`
`SAMPLES OF REFERENCES / '[MMUNO—DEFICIENT MICE STUDIES
`
`170-ESTRADIOL
`
`ACTA Ncurochiurgica. 140(1): 82-86. I998
`Acta Physiologiea Scarrdinavica. I76 (3): [Tl-184. 2002
`American Association for Cancer Research (AACR). 2003
`American Journal of Obstetrics and Gynecology, I84 (3): 303-303. 200]
`American Journal of Pathology, I53 (6): l993—20I)6. [998
`American Journal of Pathology. I53 (2): 639-646. 200]
`American Journal of Pathology. I61 (3): 909-9 I 3. 2002
`American Journal ofPatltology. I63 (5): I?l3-I719. 2003
`An1ericanJournal of Pathology. I63 (6): 253I—254 I . 2003
`American Journal of Physiology: Endocrinology and Metabolism. 282
`(I): E139-E146. 2002
`American Journal of Physiology: Endocrinology and Metabolism. "283
`(4): E623-E630. 2002
`American Journal of Physiology: Gastroi nlcstinal and Liver Physiology.
`290 (2): G269—G2?6. 2006
`American Journal of Physiology: Heart and Circulatory Physiology, 284
`(5): H1560-H1569. 2003
`American Journal of Physiology: Heart and Circulatory Physiology. 290
`(5): H2043-H2050. 2006
`American Journal of Physiology: Renal Physiology. 233 (S): F934—F'943.
`2002
`American Journal of Physiological Society. 102: 1337- I393. 200'?
`American Society for Nutritional Sciences, I34: I929-I934. 2004
`Anti-Cancer ‘Drugs, I5 (I0): 99 I-996. 2004
`Anticancer Research. 8 (6): 1233-1240. 1988
`Applied Spectroscopy. 58 (I): I-9. 2004
`Arteriosclerosis. Thrombosis. and Vascular Biology. '25: I910 I9 I6.
`2005
`
`|59|
`
`Biochemical and Biophysical Research Connnunications. 29'! (I): 83-
`90. 2002
`Bioclrernical and Biophysical Research Conttnunications. 329 (3): B88-
`89".-’. 2005
`Biochemical Pharmacology. 5? (3): 309-3| 2. I999
`Biochemical Pharmacology. 5? (9): 1042-1053. [999
`Biochimica et Biophysica Acta (BEA): Molecular Cell Re.-cenrclt.
`(I-31:109-118. 2002
`Biological Procedures Online. 5 (I): 21 I-22|. 2003
`Brain Research. [022 (I-2): I48-I56. 200-1
`Brain Research. I052 (1): I05-I II. 2005
`Brain Research. 9| 2 ( l ): 79-83. 200!
`Breast Cancer Research and Treatment. 45 (2): 99-107. I99’?
`Breast Cancer Research and Treatment. 60 (I): 15-28. 2000
`Breast Cancer Research and Treatment, 78 (I): I-6. 2003
`Breast Cancer Research and Treatment. 78 ('2): 205-ZI6. "2003
`Breast Cancer Research and Treatrnent, 79 (3): 281-299, 2003
`Breast Cancer Research and Treatment. 85 (3): 229-233. 2004
`Breast Cancer Research and Trcauncnt. 92 (2): HI -I49. 2005
`Breast Cancer Research and Treatment. 92 (3): 251-263. 2005
`Breast Cancer Research. 2 (2): I39-I48
`Breast Cancer Research. 7 (6): R940-R952. 2005
`British Journal of Cancer, 64 (6): |0l9— I024. I999
`British Journal 0fCanccr. 30 (7): I005- l0I I. 1999
`British Journal oI'Cancer. 86 (1): I36- 142. 2002
`British Journal of Cancer, 83 ('3): 470-4'? I , 2003
`British Journal of Cancer, 89 (2): 335-390. 2003
`British Journal of Cancer. 90 (1 I): 2232-2242. 2004
`British Journal of Cancer. 90 (2): 430-435. 2004
`British Journal of Pharmacology, I“-10(1): 195-20 I . 2003
`
`1713-ESTRADIOL (cc-nt.)
`
`Cancer Letters. I09 (1-2): 223-230. 1996
`Cancer Letters. I32 (I-2): I07-I 12. I998
`Cancer Letters. I79 (I): 43-49. 200.’!
`Cancer Letters. 189 (I): 49-57. 2003
`Cancer Research. :18 (4): I 143-I I4?. 1988
`Cancer Research. 53 t_ I4): 3229-3232. I993
`Cancer Research. 53 (2): 233-290, 1993
`Cancer Research. 53 (9): 2 I 68-2 I77, I993
`Cancer Research. 53 (9): 2]7II—2I87. I993
`Cancer Research. 54 ('2| ): 55| I-55]-‘I. I994
`Cancer Research. 55 (18): 4146-4150. I995
`Cancer Research. 56 (I9): 4328-433 I, I996
`Cancer Research. 56 (9): 1965- I969. I996
`Cancer Research. 5? (22): 5155-5161. 199?
`Cancer Research, 53 (2): 352-36 I. [993
`Cancer Research, 58 (21): 435 I -435?. I998
`Cancer Research. 59 [I5]: 3646-365]. I999
`Cancer Research. 59 (I9): 5023-5029, I999
`Cancer Research. 59 (6): 1347- I 355, 1999
`Cancer Research. 60 (I): 4246. 2000
`Cancer Research. 60 ( l I ): 308l—3l}8'l. 2000
`Cancer Research, 60 [I 2): 3254-3261, 2000
`Cancer Research. 60 ( I 7): 4804-481 I. 2000
`Cancer Research. 60 (2): 213-2 I 8, 2000
`Cancer Research. 60 (24): 2094-7098. 2000
`Cancer Research. 61 ( I0): 4229-41237, 2001
`Cancer Research. 6| (2): 532-537, 2001
`Cancer Research. 61 (24): 8882-8895. 2001
`Cancer Research, 6| (5): l'l86—I'l90. 200I
`Cancer Research. 6] (6): '25-41255 I. 200i
`Cancer Research. 6| (2): 2857-2861. 200]
`Cancer Research. 6] (7): 29 I7-2922, 2001
`Cancer Research. 61 (8): 3443-3449. 200I
`Cancer Research, 62 (I3): 3868-3875. 2002
`Cancer Research. 62 I5): 1439- I442. 2002
`Cancer Research, 62 (6): I904-I909, 2002
`Cancer Research. I52 U): 1948- [95 I. 2002
`Cancer Research. I52 ('r'): 2l4l—2l50. 2002
`Cancer Research. 63 (10): 2425-2435. 2003
`Cancer Research, 63 (I9): 65 I6-6522, 2003
`Cancer Research. 63 (24): 8242-8740. 2003
`Cancer Research. 63 (24): 39] 2-3921. 2003
`Cancer Research. 63 (9): 2 I 39-2144, 2003
`Cancer Research. 64 (I): 415-422. 2004
`Cancer Research, 64 (I I): 3958-3965, 2004
`Cancer Research. 64 ( I2): 4302-4308, 200-1
`Cancer Research. 64 (_ I3): 4539-4546, 2004
`Cancer Research, 64 I'_ 14): 4875-4836. 2004
`Cancer Research. 64 (I2): 6| 27-6| 36, 2004
`Cancer Research. 64 [I 7]: 6200-6206. 2004
`Cancer Research. 64 ('3): 977-984. 2004
`Cancer Research, 64 (4): I419-I424. 2004
`Cancer Research. 64 (3): I737-l 743. 2004
`Cancer Research. 65(1): 18-25. 2005
`Cancer Research. 65 (1): 31?-324. 2005
`Cancer Research. 65 (21): 9962-9970. 2005
`Cancer Research. 65 (3): 6BI—68S. 2005
`Cancer Research. 65 (4): 1459-1470. 2005
`
`Additional references for 178-Estradiol on pages 112-117
`
`AstraZencca Ex. 2044 p. 84
`
`

`
`SAMPLES OF REFERENCES / IMMUNO-DEFICIENT MICE STUDIES
`
`170-ESTRADIOL (cont)
`
`1?!)-ESTRADIOL (cont.)
`
`Cancer Research. 65 (9): 38 I 5-3822. 2005
`Cancer Research. 66 (6): 3221-3227. 2006
`Cancer Re—sea.rcl1. 66 (7): 3667-3672. 2006
`Cancer Research. 66 (9): 4789-4294. 2006
`Cancer Research. (:6 (I2): 6063 -60'! I . 2006
`Cancer Rescarcli. oi (21): l0230- lCl24t), 2007'
`Cancer Research. 67 (I8): 8439-3443. 2007
`Cancer Research. 67 (I I): 5505-5512. 2007
`Cancer Research. 67 (9): 4254-4263. 2007
`Cancer Research. 6')‘: 5365-5371, 200'!
`Cancer Research. 6'.-' ('24):
`I H32-I I?-ll . 2007
`Cancer Research. 67 (7): 3412-3421. 2007
`Cancer Research. 67: 3062-207i . 2007
`Cancer Research. 67 (30): 9929-9936. 2007
`Cancer Research. 6'? (23): I ]463—l 1469. 200’?
`Cancer Research. 67 (IT): 3032-8042. 2007?
`Cancer Science. 94 (6): 501-507, 2003
`Cancer Therapy: Preclinical. I3 (6): I892-I902. 2007
`Cancer. Chemotherapy. and Pharmacology. 43 (3): |33- I97‘. [999
`Cancer. lmniuriology. and lmrnunuthcrapy. SI (I0): 55?-564, 2002
`Carcinogenesis. l9(ll]: 1895-I900. I998
`Carcinogenesis, 26 (3): 58?-595. 2005
`Carcinogenesis. 26 (4): T.-’ I -728. 2005
`Carcinogenesis, 26 (9): I521’. I535. 2005
`Cell. 130131)-823. 200?
`Cell and'I‘issue Research. 304: 5 I -58. 200i
`Cell Growth and Differentiation. 4 (3): [93-201. I993
`Cell Proliferation. 34 (4): 223-233. 200]
`Ci)l3tTllSU')" and Biology.
`I
`I (6): 782-792. 2004
`Circulation Research. 93 (2): l':'(J-I".-"F. 2003
`Circulation. 102 (24): 2983-2939. 2000
`Circulation. I03 (3)! 435-44]. 200i
`Circulation. I0‘! (24): 3059-3065. 2003
`Circulation. 108(25): 3115-312%. 2003
`Circulation. lll (I2): I492-I-198.2005
`Circulation. 9'.’ (22): 219?-220i. 1998
`Clinical and Experirnentnl Metastasis. I7 (4): 323-330. 1999
`Clinical and Experimental Metastasis. 2| (I): 65-74. 2004
`Clinical Cancer Research. )0 (I 2): -1038-4047. 2004
`Clinical Cancer Research, I0 (I8): 6053-6065. 2004
`Clinical Cancer Research. [0 (22): 7703-271 l. 2004
`Clinical Cancer Research. I0 (23): 8059-3067. 2004
`Clinical Cancer Research. [0 (4): [S30-I534. 2004
`Clinical Cancer Research. I l (I 2): -l60| -4609. 2005
`Clinical Cancer Research. I
`I ([5): 5390-5395. 2005
`Clinical Cancer Research. 1 I (2): 931-936. 2005
`Clinical Cancer Research, I
`I (22): 3195-8200, 2005
`Clinical Cancer Research. I
`I (4): 1483-1489. 2005
`Clinical Cancer Research. I
`I (S): I933-I939. 2005
`Clinical Cancer Research. I 1 (9): 3392-340i. 2005
`Clinical Cancer Research. 12 (I): 28[-288. 2006
`Ciinicnl Cancer Research. I2 (1 I): 3280-3287. 2006
`Clinical Cancer Research. ill (9): 2245-225i . i998
`Clinical Cancer Research. 5 (1 I): 3632-3638. I999
`Clinical Cancer Research. 6 (I I): 4373-4380. 2000
`Clinical Cancer Research. 6 (9): 3621-3623. 2000
`Clinical Cancer Research. 7 (10): 3 [(56-3177. 200]
`Clinical Cancer Research. '3 ll 1): 3544-3550. 200]
`
`Clinical Cancer Research. ‘I’ (I I): 3613-3624. 200]
`Clinical Cancer Research, ‘I’ (4): I06] -1072. 2001
`Clinical Cancer Research, ? (7): 2050-2056. 3001
`Clinical Cancer Research. 8 (I1): I008-I013. 2002
`Clinical Cancer Research. 3 (5): I003-1007. 2002
`Clinical Cancer Research. 8 (5): I008-I013. 2002
`Clinical Cancer Research. 3 (6): I932-1939. 2002
`Clinical Cancer Research, 9 (15): 5514-5520. 2003
`Clinical Cancer Research. 9 (5): 1327-1334. 2003
`Clinical Cancer Research. 9 (6): 2350-2356. 2003
`Clinical Cancer Research. 9 (8): 2933-2939. 2003
`Clinical Cancer Research. 12 (I 1): 3280 - 3287. 2006
`Clinical Cancer Rescarcli. )3 (I6): 4909-4919. 200?
`Clinical Cancer Research. I3; 5020-5027. 200?
`Clinical Cancer Researcli. l3 (3'): I061-I067, 200‘!
`Cytokine. 35 (2): 43-5] . 2004
`Department of Neurology Series of Reports, 60: 2002
`Development. 132 ( I7): 3923-3933. 2005
`Developmental Brain Research. I22 (2): I49-I55. 2000
`Diabetes. 5! (7): 2158-2169. 2002
`Endocrinology, I35 (6): 26I 5-2622. I994
`Endocrinology. I36 (I I): 4996-5003. [995
`Endocrinology. I4] (2): 309-820. 2000
`Endocrinology. I42 (4): I497-1505. 200i
`Endocrinology. I43 (2): 636-606. 2002
`Endocrinology. l—'-13(3):
`I I3 I -| 143. 200'}
`Endocrinology. I48 (8): 3618-3624. 200?
`Estrogen. Social Recognition Memory. and I-[PA Axis. 2002
`Estrogen. Social Recognition Memory. and HPA Axis. 2003
`European Journal of Cancer. 34 ( 3): 334-383. 1993
`European Journal of Cancer. 37 (I2): I5-15- I553. 200]
`European Journal of Endocrinology. [42 (4): 301-3 I4. 2000
`European Journal of Heart Failure. 7 (7): I079-1084. 2005
`Experimental Eye Research. 80 (3): -113-123. 2005
`Experimental Neurology. 19? (1): (91205. 2005
`FASEB Journal Express. [8 (3): 565-567. 2004
`FASEB Journal. 16(6): 555-564.2002
`Federation of European Biochemical Societies (FEES) Letters. 440 (3):
`403-408. I998
`Fertility and Sterility. 13(5): 973-973. 2002
`Fertility and Sterility. 80 (Supplement 2): 832-838. 2003
`Fertility and Sterility. 82(3): 673-678. 2004
`Crastroenterology. I2? (_ I ): 239-249. 2004
`Gene Therapy. 5 (2): 240-246. 1998
`Gene Therapy. 7 (3): 24| -243. 2000
`Genes Chroniosonics and Cancer.
`I
`Genome Biology. Tr’ (4): 2006
`Hormones and Behavior. 47 (3): 350-357. 2005
`Hypertension. 36 (S): 224-779, 2000
`Hypertension. 42 I26}: 1 l5':'—l I63. 2003
`International Journal of Cancer. I07 (2): I77-I82. 2003
`lntemational Journal of Cancer. 10? (4): 535-540. 2003
`International Journal of Cancer. I08 (I): 3-14. 2003
`International Journal of Cancer. l()8 (6): 922-929. 2004
`International Journal of Cancer.
`I I0 (5): 767-724. 2004
`International Journal nf Cancer. H3 (2): 316-328. 2005
`International Journal of Cancer.
`I I6 (6): 847-352. 2005
`International Journal ofCancer. I I8 (5): l3l6-1320. 2006
`
`( I )t 48-58. [939
`
`Additional references for 170-Estradiol on pages 112-117
`
`75
`
`AstraZeneca Ex. 2044 p. 85
`
`

`
`SAMPLES OF REFERENCES I IMMUNO-DEFICIENT MICE STUDIES
`
`I70-ESTRADIOI. (cont)
`
`1711-ESTRADIOL (cont.)
`
`International Journal of Cancer. 66 (S): 669-627. I996
`International Journal of Cancer. 8] (3): 309-313. [999
`lntentational Journal of Cancer. 37 (5): 716-723. 2000
`International Journal of Gynecological Cancer. I3 (2): I03-I I0. 2003
`International Journal of Oncology. 20 (4): SI3-tilt‘-l. 2002
`International Journal of Oncology. 21 (I): T3-80, 2002
`International Journal of Oncology. 22 (4): 835-341. 2003
`Investigative Opthalmology and Visual Science. 44 (3): I22 I - I 229. 2003
`Investigative Opthalrnology and Visual Science. 44 (4):
`l'?40- l'l'4-6. 2003
`JNCI. 99 (9): 694-705. 200?
`Journal of Applied Physiology. 97 (.2): 756-763. 2004
`Journal of Applied Physiology. 97 (4): I234-I 244. 2004
`Jnumal of Applied Physiology. [02 (S): I337-1393. 2007
`Journal of Biological Chemistry. 22'! (42): 39858-39866. "2002
`Journal of Biological Chemistry. 269 (42): 26449-26455. I994
`Journal of Biological Chemistry, 276 (26): 23263-‘Z3763, "2001
`Journal of Biological Chemistry. 276 (45): 42259-4226)‘. 200]
`Journal of Biological Chemistry. 277 (42): 39853-39866. 2002
`Journal of Biological Chemistry. 278 (9)1 7580-7590. 2003
`Journal of Biological Chemistry. 279 (10): 8602-8607, 2004
`Journal of Biological Chemistry. 280 (29): 22022-22028. 2005
`Journal of Biological Chemistry, 232 (I9): 14328-l433o. 200?
`Journal of Cardiovascular Electropsysinlogy. I3 (3): 276-280. 2002
`Journal of Cardiovascular Phamtacology. 43 (5): 607-6| S. 2004
`Journal ofCell Biology. I43 (4): T.-'9-?90, 2000
`Journal of Clinical Endocrinology and Metabolisnt. 89(3): I039-I095,
`2004
`
`Journal of Clinical Investigation. I06 (1 I): I373-I379. 2000
`Journal of Clinical Investigation. I06 (6): 263-27! , 2000
`Journal of Clinical Investigation. )0? (3): 333-340. 2(l()|
`Journal of Clinical Investigation. I09 (I2): I625-I633. 20l)2
`Journal of Clinical Investigation. 109(4): 541-548. 2002
`Journal of Clinical Investigation. H0 (4): 453-462. 2002
`Journal of Clinical Investigation. I I6 (I): 209—2l6. 2006
`Journal ofClinicaI Investigation. I I7 (I): 2l8-223. 2007
`Journal of Immunological Methods. 272 (I-2): I77-IST. 2003
`Journal of Immunology. I52 (5): 23??-2384. I994
`Jnumaloflmmunology, I60 (l0):5{]9B-5|04. I998
`Journal of Immunology. [66 (3): 2080-2089. 200i
`Journal of Immunology. I67 (4): I386-1390. 2001
`Journal of Immunology. I74 (10): 6023-6029. 2003
`Journal oflrnmunology. I75 (3): I415-I423. 2005
`Journal of Immunology. I76 ('5): 2703-27 I0. 2006
`Journal of Inorganic Biochemistry. 77 (I ):
`l 17-120. [999
`Journal of Lipid Researcl1.4'l ('4): 723-786. 2006
`Journal of Magnetic Resonance Imaging (JMRI). 6(1): I95-202. I996
`Journal ofNeurocl1emist.ry. 79 (-1): 296-303. 200i
`Journal of Ncurochemisny. 30(1): I9 1- I96. 2002
`Journal of Neurocltetnislry. B"? (4): 1052-1055. 2003
`Journal of Neuro—Oncology. 34: 221-231. I997
`Journal of Neuroscience Research. 77 (I): I I9- I26. 2004
`Journal of Neuroscience Research. ‘.-'9 (3): 279-286. 2005
`Journal of Neuroscience. 22 ( I0): -4095-4 I02. 2002
`Journal of Nuclear Medicine. 44 (9): 1469- I478, 2003
`Journal ofhluclear Medicine,-46(10): 1719-1726. 2005
`Journal of Nutrition. I31 (9): 235!-2357. 200]
`Joumal of Nutrition, 132 (8): 2246-2250, 2002
`
`Journal of Steroid Biochemistry and Molecular Biology. 84 (2-3): 36I -
`36?. 2003
`Journal of Steroid Biochemistry and Molecular Biology. 94 (5): 439-
`498. 2005
`Journal of Steroid Biochemistry. 12'? (I-3): 493-493. I98‘?
`Journal ol‘ the American College of Cardiology, 4| ( I I): 2034-2092,
`2003
`Journal of the National Cancer Institute. 96 (I0): 739-749. 2004
`Journal ofthc National Cancer Institute. 96 ( I I): 875-828. 2004
`Journal of the National Cancer Institute. 96 (3): 210-213. 2004
`Journal ofvirology. 73 (6): 5 I44-5 I 48. I999
`Laboratory Animal Science. 47 (I ): 82-35. 1997
`I_.nng-Term Esuogen Replacement and Social lvleniory. 2004
`Luminescence. I3 (4): 213-223. 2003
`Magnetic Resonance in Medicine, 46 (I): 3 I -38. 2001
`Metabolism. 52 (6): 659-66| . 2003
`Molecular and Cellular Biology. 23 (19): 6837-6900. 2003
`Molecular Cancer. 65 (6): 2007
`Molecular Cancerflterapeutics. I (4): 239-246. 2002
`Molecular Cancer Therapeutics. 1 (6): 3??-334, 2002
`Molecular Cancer Therapeutics. 2 (3): 729-737. 2003
`Molecular CanccrThcrapcutit:s. 3 (I2): l565- I575. 2004
`Molecular Cancer Therapeutics. 3 (3): 233-244. 2004
`Molecular Cancer Therapeutics. -1 (l2): |837- I 849. 2005
`Molecular Cancer Therapeutics. 5 (I I: I-7. 2006
`Molecular Cancer Therapeutics. 5 (2): 3 I 7-328. 2006
`Molecular Cancer Therapeutics. 5 (3): 685-692. 2006
`Molecular Cancer Therapeuucs. 6 (9): 2458-2467. 200"!
`Molecular Carcinogenesis. I9 ( I 1: 54-66. [997
`Molecular Endocrinology. 20(1): I4-34. 3006
`Molecular Endocrinology, 20 (5): 996-1008. 2006
`Molecular Human Reproduction. 3 (4): 333-342. I997
`Molecular Human Reproduction. 5 (I2): [I4]-ll-19. I999
`Molecular Pharmacology. 65 (3): 730-743. 2004
`Molecular Tlierapy. 9 (4): 540-547, 2004
`Nature Biotechnology. 22 (3): 3l3-320. 2004
`Nature Biotechnology. 22 (6): ‘lot-‘J06. 200:)
`Nature Medicine. 6 (4): 443-446, 2000
`Nature Medicine. 9 (8): I026 I032. 2003
`Nature. 406 (6792): 742-747, 2000
`Neoplasia. 3 (2): 143- I53. 2001
`Ncoplasitt. 9 (6): 43?-494. 2007
`Neurobiology . 24 (7'): 97?-983. 2ll()3
`Neuroendocrinology. 78 (3): I4'i'- I 58. 2003
`Neuroreport. ll) (6): 13694372. 1999
`Neuroreport. I5 (1): 39-93. 200-1
`Neuroscience. )2] (3 J: 659-666. 2003
`NMR in Biornodicine. I5 (2): I 14-] I9. 20(l2
`NMR in Biomedicinc. I? (-‘l): I20-180. 2004
`Nuclear Medicine and Biology. 23 (4): 397-399. 20Ill
`Nuclear Medicine and Biology. 31 (6): ‘J6! -T70, Ellllai
`Nuclear Medicine and Biology. 32 (1): 51-58. "2005
`Obesity Research. I2 (4): T I6-724. 2004
`Oncogene. IS (IT): 2093-2I(l8. 1997
`Oncogene. l7(l8_): 2235-2249. I998
`Oncogene. ll-l(l3): 22-ll-235i. I999
`Oncogene. |8(39):5-135-54-47. I999
`
`Additional references for 170-Estradiol on pages 112-117
`
`AstraZeneca Ex. 2044 p. 86
`
`

`
`SAMPLES OF REFERENCES I IMMUNO—DEFICIENT MICE STUDIES
`
`170-ESTRADIOL (conL}
`
`TAMOXIFEN
`
`Oncogene. I9 (38): 433?-43-‘IS. 2000
`Oncogene. l9(3): I605-I612. 2000
`Oncogene. 2! (I5): 2805-2814. 2002
`Oncogene. 21 I25): 4000-4008. 2002
`Oncogene. 2| (8): I159-I I66. 200.?
`Oncogene. 23 (ST): 9295-9302. 3004
`Oncogene. 24 (I6): 26'I"I'-2633, 2005
`Oncogene. 24 (19): JI66-3176. 2005
`Oncogene. 24 (5): ‘I46-760, 2005
`Otolaryrigology - Head and Neck Surgery. I20 (2): 262-264. I999
`Physiology and Behavior. TF4 (4-5): 653-653. 200|
`PNAS. 8'? (6): 2314-2318. I990
`PNAS. 93 ( I3): 624?-625 I . I996
`PNAS. 95 (5): 2643-2652. 1998
`PNAS. 95 (8): 4579-4583. I998
`PNAS. 96 (23): I3023-13028. 1999
`PNAS. 96 (26): I513]-|5l36. I999
`PNAS. 9'? (4): H54-1759. 2000
`PNAS. 97 (6): 2'IIJ3—2'r'03. "2000
`PNAS. 98 (23): I339] -13395. 200]
`Proceedings of the Anicrican Association of Cancer Research (AACR).
`28: 235. I98’?
`Protcornics. ‘I (7): EH5-2183. 2004
`Regulatory Peptides. I24 ( I): 7-))‘. 2005
`Society for Experimental Biology & Medicine: 754-7'6]. 2007
`The Journal of Nuclear Medicine. 46 (I I): I866-I87]. 1005
`Toxicological Sciences. 54 12): 493-499. 2000
`Toxicological Sciences, 63 (2): 295-303. 2002
`
`
`
`American Jonrntll of Pathology. l5+B446:B5303 (6): I993-"2006. I993
`American Joumal of Pliysiology: Endncrinililogy and Metabolism. 283
`(4): E623—E630. 2002
`.u’\[‘i‘JI3I'lCi1l1 Journal of Physiology: Gastrointestinal and Liver Physiology.
`283 (I): G2?-G36. 2002
`American Journal of Physiology: Regulatory. Integrative and
`Comparative Physiology. 282 (3): R90-l—R90'I. 200]
`Breast Cancer Research and Treatment. 41 (I): Tl-79. I996
`Calcified 'I'is::uc International, 43 (6): I983
`Cancer Letters. 62 (2): I0‘!-I I4. I992
`Cancer Research. 49 (I5): 4090-4093. I989
`Cancer Researcll. 49 (17): 4765-4769. I989
`Cancer Researtli. 50 (l I): 3 l89—3 I92. 1990
`Cancer Researcli. 53 (9): 2168-2177. I993
`Cancer Reseamh. S4 (2 I): 55] I-55 I4, I994
`Cancer Research. 54 (24): 6334-6337, I994
`Cancer Research. 56 (19): 4328-4331, I996
`Cancer Research. 57 (22): 5155-5 l6l. 1997
`Cancer Research. 53 (2): 352-36] , 1998
`Cancer Research. 60 (24): T094-‘I098. 2000
`Cancer Research, 6') (‘J’): I948-195 l. ‘.1002
`Cancer Research. 63 (I0): 2425-2434. 2003
`Cancer Research. 64 (5): I'}'37- 1743. 2004
`Cancer Research. 65 (I): 18-25. 2005
`Cancer Research. 65 (3): 879-886. 2005
`Carcinogenesis. 8 (5): 699-T03. [987
`Cell Proliferation. 34 (4): 223-232. 200]
`Clinical Cancer Research. 4 (3): 69'.-'-'.-’l 1. I998
`Clinical Cancer Research, 9 (3): 2933-2939. 2003
`Endoerinology. I36 I I I): 4996-5003. 1995
`European Journal oI'Pharn1acu|og)r. 483 (2-3): 155-162. 2004
`I-Ioniione and Metabolic Research, 35 (I I112): 836-842. 2003
`Hormones and Behavior. 45 (4): ?.'.-'0—2?'?. 2004
`International Journal of Cancer. 92 (3): 3412-347. 2001
`Journal oflrnniunology. I75 (3): I-‘H5-I423. 3005
`Journal of Magnetic Resonance Imaging (J MRI). 6 (I): 195-202. [996
`Journal of NeuroeI1doi:rinology.
`I
`I (I0): B0]-803. I999
`Journal of Neuroendocrinology. 13 ('1'): 6J8-624, 2001
`Journal of Nutrition. I32 (8): 2246-3325!. 300?.
`Jounial ofsteroid Biochemistry. 27 (I-3): 493-498. [937
`Journal of the Society for Gynecologic liivestigrttion. 7 (4): 249-256.
`2000
`Microbes and Infection. 7 (3): 485-493. 2005
`MoIce1IIarBrnin Research. I08 (1-2): |2|-128.2002
`Molecular Endocrinology, I
`I (‘I’): 9] ?-92?. I99?
`Molecular Endocrinology. 20 (5): 996-1003. 2006
`Nature Immunology, 2 (1)164-68, 200I
`Nature, 4 I6 (6373): 334-338. 2002
`Neuroscience. I03 (3): 335-394, 200]
`Oncogene. 10(13): 2435-W6. I995
`Oncogene. 2| (25): 4000-4003. 2002
`Oncogene. 24 (I9): 3166-3 I 76. 2005
`PNAS. 93 (l3):62r1T-625]. [996
`Proceedings of the Anlerican Association of Cancer Research (AACR).
`‘.18: 235. I98?
`
`Additional references for 170-Estradiol on pages 112-117
`
`Additional references for Tamoxifen on page 121
`
`AstraZeneca Ex. 2044 p. 87
`
`

`
`TESTOSTERONE, Soc-DIHYDROTESTOSTERONE, FLUTAMIDE
`
`AND CYPROTERONE ACETATE
`
`PELLETS FOR TUMOR GROWTH AND REGRESSION
`
`IN IMMUNO-DEFICIENT MICE
`
`SEE PAGE 3 FOR ORDERING INFORMATION OF ANABOLIC STEROIDS
`
`It has been established that the growth and regression of androgen—dependent tumor
`
`tissue in mice is dependent upon three factors.
`
`1. The tumor tissue itself.
`
`2. A healthy and untraumatized mouse.
`
`3. Exogenous androgen or anti-hormone ready~to-implant pellets
`from Innovative Research of America.
`
`The most commonly used 60-day and 90-day pellets in mice are listed below in these charts:
`
`60-Day Release Pellets
`
`Description
`
`mglp
`
`Size
`
`Pellets
`
`Pellets
`
`Pellets
`
`Pellets
`
`
`
`Testosterone
`{See Conlrollecl Substances Page 3]:
`
`5o; -Dihyclrotestoslerone
`[Sea Controlled Substances Page 8]
`
`Flutamide
`
`Cyproterone Acetate
`
`Placebo
`
`90-Day Release Pellets
`
`Product
`
`Total Dose
`
`Pellet
`
`25
`
`50
`
`100
`
`200
`
`Description
`
`Size
`
`Pellets
`
`Pellets
`
`Pellets
`
`Pellets
`
`Testosterone
`{See Controlled Subslances Page 3}
`
`50:-Dlhydrotestoslerone
`(Sea Controlled Substances Page at
`
`Flutamlde
`
`Cyproterone Acetate
`
`Placebo
`
`Note: Other products and dosages that can also be used in mouse studies are found throughout this catalog.
`
`78
`
`Astrazeneca Ex. 2044 p. 88
`
`

`
`SAMPLES OF REFERENCES /_ IMMUN__0-IDEFICIENT MICE. STUDIES
`
`So:-DIHYDROTESTOSTERONE ("Soc-DHT}
`
`So:-DIHYDROTESTOSTERONF. (50:-Dl-IT) fcont.)
`
`American Journal of Physiology: Cell Physiology. 274 (6):
`C|S30—Cl536. 1993
`American Journal of Physiology: Cell Physiology. 2?’? ( I): C35-C42.
`I999
`
`American Journal of Physiology: Endocrinology and Metabolism. 283
`(11: I39-196.2003
`American Journal or Physiology: Endocrinology and Metabolism. 285
`(4): E312-E8 I 8, 2003
`American Journal of Physiology: Rcmll Physiology. 283 (3):
`F5 I 3-F520. ‘.2005
`Bincltimica ct Biopliysiea Acta (EBA): Gene Structuue and
`Expression. 15) 8 (1-2): ?3—T'8. 200)
`Blood. I02 (2): 480-488. 2003
`Bone, 26 (I): 27-32. "2000
`Cancer Research. 50 (23): 7'67?-768]. I990
`Cancer Rcsearclt. 52 (I9): 5|?)-SIT}. I992
`Cancer Research. 59 (I9): S030-5036. I999
`Cancer Reseantlt. 60 (2 I): 6 I 34-614! . 2000
`Cardiovascular Research. 53 (3): ‘J52-T621. 2002
`Cerebral Cortex, I3 (3): 232-296. 2003
`Developmental Brain Research. I25 ( I -2): 33-33. 2000
`Endocrinology, |30(6): 1'03-'.-‘I4. I992
`Endocrinology. l35(-1): 1605-1610. [994
`Endocrinology. [35 (6): 2615-2622. I994
`Endocrinology. I39 (2): 683-695. 1998
`Endocrinology. I-1-0 (I0): 450945 I 3. I999
`Endocrinology. I41 (I2): 4698-:1‘tl0. ‘.1000
`Endocrinology. l4l (3): 2923-2929, 2000
`Endocrinology. I42 (I I): 4652-4662. 2001
`Endocrinology. 142 (3): I273-I283. 200]
`Endocrinology. I44 (I0): 4478-4484. 2003
`Endocrinology. I44 (5): 23| I-2313. 2003
`Endocrinology. I45 ( I): 330-336. 2004
`Endocrinology, 145 (7): 3501-3522. 2004
`Endocrinology. I46 (2): 564-573. 2004
`Experimental Parasitology. I00 (4): 209-216. 2002
`Journal of Biological Chemistry. 268(18): IJSSIS-|3S64. I993
`Journal of Biological Chemistry. 275 (22): |6536-I65-12. 2000
`Journal o|'Clinica| Investigation. I03 (I 1): I697-l?ll4. 200i
`JnurnalofClinica| Investigation. III (9): I319-I327. 2003
`Journal of Endocrinology, I89 (3): 5 I 9-528. 2006
`Journal of Experimental Medicine. l‘r’5 (S): l—109—|-“H2. I991‘
`Journal oflmrnunology. IS9(_|): I-6. I99’?
`Journal of Immunology. )6? (4): 2060-2067. '200|
`Journal of Molecular Endocrinolog , 2| (2): 2|?-223. I993
`Journal of Neurobiology. 52(4): 3l2-321.2002
`
`l9l'.l|
`
`l33- I 38. I996
`
`Journal of Neurochemistry. 3}‘ (4): I052-I055. 2003
`Journal of Neuroirnrnunnlngy. I46 (I-2): I4-4-I52. 2004
`Journal of Orthopedic Research. 3 (4): 612-6lT. I990
`Journal ot'Staroid Biochemistry and Molecular Biology. 52 (6): S75-
`S80. I995
`Journal of the National Cancer Institute. 67 ( I): 5l~SI5,
`Liver. 20 (3): 228-233. 2000
`Molecular and Cellular Endocrinology. I20 (2):
`Molecular Endocrinology. l
`l (7): 9|?-927. I997
`Molecular Endocrinology, I3 (9): 1449-1459. [999
`Molecular Endocrinology. '7 (7): 898-906, I993
`Molecular Pharmacology. 65 (3): 730-743. 2004
`Neurology and Neuroscience. 2 (2): 2Tr'—2t3fi. 2002
`Neuroscience. )2? (3): 53-578. 2003
`Oneogenc. 18 (39): 5435-5447. I999
`PNAS. I00 ()6): 9-H6-9421. 2003
`PNAS. I0) (6): I673-l6?S.2004
`PNAS. 91 ([2): 5382-5386, I994
`PNAS. 93(9): 521)-52l6. 2001
`Science. 298 (5594): 843-346. 2002
`Toxicological Sciences. 76 t I): I'll-I81. 2003
`American Journal of Kidney Diseases. 29 (2): 265-272. I997
`American Journal of Obstetrics and Gynecology. I73 (5): I49 1- I493.
`[995
`American Joumnl ol‘0bstetrics and Gynecology, I84 (3): 303-308. 200i
`American Jotlmul of Physiology: Heart and Circulatory Physiology. 290
`(4): H|6l0-H1616. 2006
`Biochemical and Biophysical Research Communications. 300 (I): I6?-
`IT 1. 2003
`Biochemical and Biophysical Research Corninunicatiotis. 326 (I): I8l —
`[B12005
`Bone. [9 (2): l0'l'—) [4, I996
`British .|ournal of Urology International. 96 (7): I I26-I I30, 2005
`Cardiovascular Research. 5'.-' (1): 28-30. 2003
`Cardiovascular Research. 65 (I): l48- 157. 2005
`Cytokine. 25 (3): ll0-1 I8. 2004
`Diabetes. 54 (6): [7] ':'—l 728. 2005
`Drug Metabolism and Disposition. 34 (3): 377-482. 2006
`Experimental Neurology. 18] (2): 301-312, 2003
`Immunological Investigations. 32 (4): 259-273. 2003
`International Journal of Andrology. 25 (4): 210-214, 2002
`Journal ofTrauma. Injury. Infection. and Critical Care. 44(1): 78-85.
`I998
`
`Molecular Carcinogenesis. -l